Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway. Iterion is advancing clinical programs of tegavivint in tumor types with a high prevalence of Wnt/beta-catenin activating mutations, such as hepatocellular carcinoma. In parallel, the company has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials in acute myeloid leukemia, non small cell lung cancer, pediatric tumors and lymphoma.
External link for Iterion Therapeutics
2450 Holcombe Blvd
Houston, Texas, US
A note from our CEO, Rahul Aras.
Iterion Therapeutics is excited have started enrolling our Phase 1b/2a clinical study for tegavivint in patients with adavanced hepatocelluar carcinoma. Its a devastating disease with few therapeutic options and we hope to make a difference in the lives of these patients. To learn more please go to: https://lnkd.in/gTKwsVw5 #cancerresearch #oncologytrials #livercancer #drugdevelopment